Allarity Therapeutics will present a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026 on its Phase 2 ovarian cancer trial of stenoparib. The company also dosed first patients in February 2026 in a VA-funded Phase 2 trial of stenoparib plus temozolomide for relapsed small cell lung cancer.
A breakthrough ovarian cancer drug, mirvetuximab soravtansine, is now available on the NHS, offering extended survival and improved quality of life. The 'biological missile' therapy targets cancer cells directly, reducing side-effects compared to standard chemotherapy. Up to 400 patients in England could benefit each year.
The FDA has cleared CStone Pharmaceuticals' investigational new drug application to begin a Phase II trial of its trispecific antibody CS2009 in advanced solid tumors. The multicenter trial will evaluate monotherapy and combination regimens across nine cancer types in Australia, China, and the U.S. Initial Phase I data showed a favorable safety profile and encouraging antitumor activity.
The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.
BioNTech presented phase 2 data for HER2-directed ADC Trastuzumab Pamirtecan showing 47.9% response rate in endometrial cancer, with FDA submission planned for 2026. BioLineRx dosed first patient in phase 1/2a GLIX1 trial for glioblastoma and reported new preclinical data. Both companies presented at ASCO 2026.
The phase 3 ROSELLA trial showed relacorilant plus nab-paclitaxel significantly improved overall survival in platinum-resistant ovarian cancer by 4.1 months versus nab-paclitaxel alone. The benefit was consistent across all subgroups regardless of prior taxane exposure, leading to FDA approval in March 2026. The combination also met its progression-free survival endpoint and demonstrated a favorable safety profile.
Sensei Biotherapeutics dosed the first patient in a Phase 1b/2 trial of PIKTOR (sapanisertib + serabelisib) in HR+/HER2- advanced breast cancer. The multi-node PI3K/AKT/mTOR inhibitor previously showed a 47% overall response rate in a Phase 1b trial.
The FDA approved Keytruda and Keytruda Qlex with paclitaxel, with or without bevacizumab, for PD-L1-positive platinum-resistant ovarian-related cancers. The Phase III KEYNOTE-B96 trial showed improved progression-free and overall survival versus placebo.
Merck received FDA approval in early February 2026 for KEYTRUDA and KEYTRUDA QLEX in PD-L1-positive platinum-resistant ovarian cancer. The decision marks the first approval of a PD-1 inhibitor regimen for this setting.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07604766 |
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China |
NOT_YET_RECRUITING | PHASE3 |
| NCT07489287 |
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer |
NOT_YET_RECRUITING | PHASE1 |
| NCT07226427 |
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer |
RECRUITING | PHASE1 |
| NCT07109414 |
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) |
ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
| NCT06730347 |
A Study of Lorigerlimab in Participants With Advanced Solid Tumors |
RECRUITING | PHASE2 |
| NCT06710288 |
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer |
RECRUITING | PHASE2 |
| NCT06619236 |
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06586957 |
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors |
RECRUITING | PHASE1 |
| NCT06547840 |
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha |
RECRUITING | PHASE1 |
| NCT06515613 |
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors |
RECRUITING | PHASE1 |
